Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
dc.contributor.author | Onal, C. | |
dc.contributor.author | Li, Y. X. | |
dc.contributor.author | Miller, R. C. | |
dc.contributor.author | Poortmans, P. | |
dc.contributor.author | Constantinou, N. | |
dc.contributor.author | Weber, D. C. | |
dc.contributor.author | Atasoy, B. M. | |
dc.contributor.author | Igdem, S. | |
dc.contributor.author | Ozsahin, M. | |
dc.contributor.author | Ozyar, E. | |
dc.date.accessioned | 2023-02-21T12:41:27Z | |
dc.date.available | 2023-02-21T12:41:27Z | |
dc.date.issued | 2011-01-01 | |
dc.description.abstract | Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74\% and 71\%, respectively, and the disease-free survival (DFS) rates were 68\% and 64\%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma. | |
dc.description.issue | 1 | |
dc.description.issue | JAN | |
dc.description.pages | 156-164 | |
dc.description.volume | 22 | |
dc.identifier.doi | 10.1093/annonc/mdq310 | |
dc.identifier.uri | https://hdl.handle.net/11443/2720 | |
dc.identifier.uri | http://dx.doi.org/10.1093/annonc/mdq310 | |
dc.identifier.wos | WOS:000285414800023 | |
dc.publisher | OXFORD UNIV PRESS | |
dc.relation.ispartof | ANNALS OF ONCOLOGY | |
dc.subject | chemotherapy | |
dc.subject | combined modality treatment | |
dc.subject | non-Hodgkin's lymphoma | |
dc.subject | prognostic factors | |
dc.subject | radiotherapy | |
dc.subject | thyroid lymphoma | |
dc.title | Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
- Name:
- Treatment results and prognostic factors in primary thyroid lymphoma patients a Rare CancerNetwork study.pdf
- Size:
- 205.39 KB
- Format:
- Adobe Portable Document Format